ALS has no cure, but these treatments can help: riluzole and edaravone slow functional decline by roughly 2-3 months and 33% respectively, while multidisciplinary care, noninvasive ventilation, and feeding support extend survival. ALS (amyotrophic lateral sclerosis) kills motor neurons controlling voluntary muscle, causing progressive weakness, speech loss, and breathing failure, typically within 2-5 years of symptom onset. No drug reverses the damage. However, four FDA-approved medications plus aggressive supportive care measurably extend life and preserve independence when started early.
The Mechanism: Why Motor Neurons Die and Why Treatment Only Slows It
ALS selectively destroys upper and lower motor neurons — the cells that carry movement commands from the brain to muscle. Loss of lower motor neurons causes muscle wasting and fasciculations; loss of upper motor neurons causes spasticity and hyperreflexia. The combination is diagnostic.
The molecular cascade is only partly understood. Roughly 90-95% of cases are sporadic; 5-10% are familial, driven by mutations in genes including C9orf72, SOD1, TARDBP, and FUS. Four converging processes damage motor neurons: glutamate excitotoxicity (excess neurotransmitter overstimulates and kills cells), oxidative stress, protein aggregation (misfolded TDP-43 accumulates in most cases), and neuroinflammation.
This matters because each approved drug targets one node, not the root cause. Riluzole reduces glutamatergic signaling; edaravone scavenges free radicals. Neither repairs neurons or stops disease — they buy time by slowing the rate of decline. In plain terms: treatment bends the slope of the trajectory downward, but the trajectory still points the same way.
A non-obvious mechanism: ALS mortality is frequently respiratory, not muscular. Most patients die from respiratory failure, and the diaphragm fails silently before limb weakness becomes severe. This is why ventilation strategy, not muscle drugs, drives survival in late disease.
How Much Do the Drugs Actually Help? Quantified Context
The evidence base is modest but real. Numbers below come from pivotal trials and regulatory reviews.
Riluzole, approved 1995, extends median survival by approximately 2-3 months in pooled trials. A Cochrane meta-analysis found a 9% reduction in mortality hazard at 12 months. It is oral, inexpensive (generic), and generally first-line.
Edaravone, approved 2017, slowed functional decline on the ALSFRS-R scale by about 33% over 24 weeks in the MCI186-19 trial, limited to a specific early-stage subpopulation. It requires intravenous infusion (or oral formulation) and costs substantially more.
Tofersen, approved 2023, targets the SOD1 mutation found in about 2% of all ALS patients. It lowers SOD1 protein in cerebrospinal fluid; a 2024 extension study suggested survival benefit in fast-progressing SOD1 cases, but confirmatory long-term data remain limited.
Sodium phenylbutyrate/taurursodiol (Relyvrio) received accelerated approval in 2022, then was withdrawn from the US market in 2024 after the PHOENIX trial failed to show benefit. This is a professional caveat: not every approval survives confirmatory trials.
Nuedexta treats pseudobulbar affect (inappropriate laughing or crying), affecting 20-50% of ALS patients, and does not modify disease course.
| Treatment | Mechanism | Measured benefit | Route | Approx. annual cost (USD) |
|---|---|---|---|---|
| Riluzole | Glutamate reduction | 2-3 months survival | Oral | 1,000-3,000 |
| Edaravone | Antioxidant | ~33% slower decline (subset) | IV/oral | 140,000-160,000 |
| Tofersen | SOD1 gene silencing | Biomarker + possible survival (SOD1 only) | Intrathecal | High (specialty) |
| Nuedexta | CNS modulation | Pseudobulbar affect only | Oral | Variable |
| NIV (noninvasive ventilation) | Ventilatory support | 10-19 months median survival gain | Mask | Equipment-based |
| Multidisciplinary clinic care | Coordinated management | 6-12+ months survival vs. general care | — | Varies |
Note the disparity: the highest-cost drug delivers the smallest measured survival gain, while noninvasive ventilation — an equipment intervention, not a drug — produces among the largest. This is the most underrecognized comparison in ALS care.
The Timeline: What Happens and When
ALS progression is measured in months, and intervention timing changes outcomes. The table below reflects typical median trajectories; individual variation is wide.
| Timepoint | What happens | Clinical action |
|---|---|---|
| Onset | Focal weakness or slurred speech; diagnosis delayed | Recognize red flags; refer to neurology |
| 0-12 months | Diagnostic delay (median 10-12 months) | EMG, genetic testing (esp. SOD1, C9orf72) |
| 12-24 months | Functional decline; falls, weight loss | Start riluzole; baseline respiratory function |
| Around 24 months | Median survival from onset reported near 2-5 years | Multidisciplinary clinic enrollment |
| Respiratory decline | FVC drops; orthopnea, morning headache | Initiate NIV when FVC < 50% predicted |
| Bulbar stage | Dysphagia, aspiration risk | Feeding tube discussion (gastrostomy) |
| Late stage | Respiratory failure | Palliative and hospice planning |
The respiratory threshold is concrete: noninvasive ventilation is typically started when forced vital capacity (FVC) falls below 50% of predicted, or when symptoms of hypoventilation appear. Starting earlier can preserve quality of life.
Respiratory and Nutritional Support: The Biggest Survival Levers
Two supportive interventions outperform every approved drug in measured survival.
Noninvasive ventilation (NIV) extended median survival by 10-19 months in observational cohorts when tolerated. The mechanism: it reduces work of breathing and prevents nocturnal hypoventilation that quietly damages organs. Tolerance is the limitation — 20-30% of patients cannot adapt to the mask.
Enteral nutrition via gastrostomy slows weight loss and reduces aspiration. Studies associate feeding tube placement with survival benefit of several months, especially in bulbar-onset disease. The caveat: timing matters, and placement late in respiratory decline carries higher procedural risk.
Multidisciplinary ALS clinics — combining neurology, pulmonology, speech therapy, nutrition, and palliative care — are associated with survival gains of 6-12 months versus general neurology care in observational data. This is care coordination, not a drug, and it is the single most duplicated finding in ALS outcomes research.
Variations and Edge Cases: Not All ALS Is the Same
ALS is a syndrome, not one disease. Subtypes alter prognosis and treatment choice.
Bulbar-onset ALS (about 25% of cases) begins with speech and swallowing; median survival is shorter, around 2-3 years from onset. Limb-onset ALS progresses more slowly. SOD1-mutant familial cases are the only group with a gene-targeted therapy (tofersen). C9orf72 expansion, the most common genetic cause, is associated with frontotemporal dementia in some families.
Age modifies trajectory: onset before age 40 is rare (about 10% of cases) and often slower. Juvenile ALS, onset under 25, is very rare and genetically distinct.
Common Misconceptions and One Corrected Threshold
A widespread misconception: ALS is purely a muscle disease. It is a motor neuron disease; muscle wasting is a downstream effect, which is why exercise can preserve function but cannot stop progression. Overexercising can accelerate fatigue.
Another corrected point: many patients assume riluzole "does nothing" because the survival gain sounds small — 2-3 months. But that figure is a median across populations; individual response varies, and early initiation yields larger absolute benefit. Do not stop riluzole based on the median alone; discuss it with your neurologist.
Reconciling thresholds: the 50% FVC figure for starting NIV refers to percent of predicted lung capacity, whereas the "2-3 months" riluzole figure refers to median survival extension, and the "33%" edaravone figure refers to decline rate on a functional scale — these measure different things and should not be compared as if on one ruler.
What to Actually Do: Concrete Actions After Diagnosis
ALS care is time-sensitive. These steps are supported by consensus guidelines and observational outcome data.
- Get a second opinion at an ALS multidisciplinary clinic within weeks, not months.
- Request genetic testing, especially if familial history or young onset, to check SOD1 eligibility for tofersen.
- Establish baseline FVC and start NIV screening early, before symptoms of hypoventilation appear.
- Discuss riluzole immediately as first-line therapy; it is cheap and has decades of safety data.
- Start a feeding and weight-monitoring plan before significant weight loss, since weight loss predicts faster decline.
- Address pseudobulbar affect and depression proactively; both are treatable and underrecognized.
Limitations: What These Treatments Cannot Do
No approved therapy halts ALS. The best combinations slow decline; they do not reverse it. Disease-modifying effects remain modest, and the highest-profile recent failure — Relyvrio's 2024 withdrawal — underscores how fragile the evidence base is.
Trial eligibility excludes many patients (advanced disease, respiratory failure), so approved benefits may not generalize. Costs are a real barrier: edaravone at USD 140,000-160,000 annually is inaccessible to many, and insurance coverage varies.
Finally, prognosis statistics are population medians, not individual destinies. A meaningful minority of patients survive beyond 10 years, and supportive care — ventilation, nutrition, multidisciplinary coordination — is the variable most within a patient's control. ALS has no cure, but these treatments can help, and the combination of early drugs plus aggressive respiratory and nutritional support is where survival gains concentrate.